Gli1/DNA interaction is a druggable target for Hedgehog-dependent tumors

Area of Science:

• Oncology
• Molecular Biology
• Biochemistry

Background:

• Hedgehog signaling is crucial for development and stemness, but its deregulation is implicated in various cancers.
• Aberrant Hedgehog signaling activation, often through the effector Gli1, drives tumor growth.
• Targeting downstream effectors like Gli1 is a critical goal for novel cancer therapies.

Purpose of the Study:

• To elucidate the structural basis of Gli1's DNA binding mechanism.
• To identify small molecules that can inhibit Gli1 activity at a downstream level.
• To evaluate the therapeutic potential of such inhibitors in Hedgehog-dependent tumors.

Main Methods:

• Structural analysis of Gli1 for DNA interaction.
• Screening for small molecules that bind to Gli1's zinc finger domain.
• In vitro and in vivo studies on cancer cell growth and stem cell properties.
• Assessment of Glabrescione B's effect on Gli1-DNA interaction.

Main Results:

• The structural requirements for Gli1 binding to DNA were clarified.
• Glabrescione B was identified as the first small molecule to bind Gli1's zinc finger.
• Glabrescione B effectively inhibits Gli1 activity by disrupting its DNA interaction.
• Glabrescione B demonstrated potent inhibition of Hedgehog-dependent tumor cell growth and self-renewal in vitro and in vivo.

Conclusions:

• Understanding Gli1 structural requirements enables targeted pharmacologic interference.
• Glabrescione B represents a promising therapeutic agent for blocking aberrant Hedgehog signaling.
• Targeting Gli1-DNA interaction offers a novel strategy for cancer treatment.